Outset Medical (OM) to Release Earnings on Wednesday

Outset Medical (NASDAQ:OM) is projected to issue its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $28.90 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Outset Medical Stock Up 3.3%

Shares of NASDAQ:OM opened at $4.65 on Tuesday. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The firm has a market cap of $84.40 million, a P/E ratio of -0.36 and a beta of 2.07. Outset Medical has a 12 month low of $3.10 and a 12 month high of $21.98. The company’s 50-day moving average price is $4.44 and its two-hundred day moving average price is $9.70.

Insider Activity at Outset Medical

In other news, General Counsel John L. Brottem sold 9,314 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $47,687.68. Following the completion of the transaction, the general counsel directly owned 36,957 shares in the company, valued at approximately $189,219.84. The trade was a 20.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Marc Nash sold 5,375 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $27,520.00. Following the completion of the sale, the executive vice president directly owned 42,785 shares of the company’s stock, valued at approximately $219,059.20. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 35,989 shares of company stock worth $180,073. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Outset Medical

Several institutional investors and hedge funds have recently made changes to their positions in OM. JPMorgan Chase & Co. raised its stake in Outset Medical by 662.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock worth $162,000 after buying an additional 7,344 shares during the period. Legal & General Group Plc bought a new stake in shares of Outset Medical in the second quarter worth about $34,000. Rhumbline Advisers acquired a new stake in shares of Outset Medical during the second quarter worth about $499,000. New York State Common Retirement Fund bought a new position in shares of Outset Medical during the 2nd quarter valued at about $108,000. Finally, Quantbot Technologies LP bought a new position in shares of Outset Medical during the 2nd quarter valued at about $152,000.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday. Stifel Nicolaus lowered their target price on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 7th. Royal Bank Of Canada restated a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a research report on Wednesday, December 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Outset Medical in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Outset Medical presently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.